Avalo Therapeutics (AVTX) saw a massive institutional accumulation cluster in Q2 2026, with 11 buyers adding $180.7M in net new holdings versus only 3 sellers trimming $4.1M. The buying was dominated by mega-passive funds (State Street, Fidelity, BofA, Goldman Sachs, Northern Trust) all doubling or adding positions, alongside quant funds RenTech and Citadel. This cluster follows the company's Q2 earnings report 11 days ago, which highlighted a strong $472M cash runway into 2029 and plans to initiate a Phase 3 program for abdakibart in hidradenitis suppurativa, outweighing the EPS miss for this pre-revenue biotech. The active-vs-passive mix is heavily passive, but the sheer scale ($180.7M net inflow) and the cross-filing amplifier (inst-earnings + inst-offering context) support a bullish read-through, though the 45-day 13F lag means positions may have been adjusted since quarter-end.
Executive Summary
Avalo Therapeutics (AVTX) saw a massive institutional accumulation cluster in Q2 2026, with 11 buyers adding $180.7M in net new holdings versus only 3 sellers trimming $4.1M. The buying was dominated by mega-passive funds (State Street, Fidelity, BofA, Goldman Sachs, Northern Trust) all doubling or adding positions, alongside quant funds RenTech and Citadel. This cluster follows the company's Q2 earnings report 11 days ago, which highlighted a strong $472M cash runway into 2029 and plans to initiate a Phase 3 program for abdakibart in hidradenitis suppurativa, outweighing the EPS miss for this pre-revenue biotech. The active-vs-passive mix is heavily passive, but the sheer scale ($180.7M net inflow) and the cross-filing amplifier (inst-earnings + inst-offering context) support a bullish read-through, though the 45-day 13F lag means positions may have been adjusted since quarter-end.
Key Financial Metrics
Institutional Positions
Net institutional flow: $176.6M
▲ Buyers (11)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| State Street | DOUBLED | +3932.3% | $53.4M | $52.3M |
| Fidelity | ADD | +77.1% | $94.3M | $51.3M |
| BofA | DOUBLED | +197.6% | $35.4M | $25.8M |
| Geode | DOUBLED | +550.5% | $20.4M | $17.9M |
| Goldman Sachs | DOUBLED | +1474.4% | $17.5M | $16.6M |
▼ Sellers (3)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| JPMorgan | NEAR_EXIT | -90.7% | $2.7M | -$2.4M |
| Deutsche Bank | TRIM | -72.6% | $2.2M | -$1.5M |
| Aberdeen Group | TRIM | -28.8% | $2.6M | -$305.5K |
Key Facts
- 11 institutional buyers added $180.7M in net new AVTX holdings in Q2 2026, while only 3 sellers trimmed $4.1M
- State Street DOUBLED its position by 3,932% to $53.4M; Fidelity added 77% to $94.3M; BofA doubled to $35.4M
- RenTech doubled its stake to $6.6M; Citadel added 67% to $6.0M
- JPMorgan nearly exited (-90.7%), Deutsche Bank trimmed -72.6%, Aberdeen trimmed -28.8%
- Cluster follows Q2 2026 earnings (8-K filed 11 days ago) showing $472M cash runway into 2029 and Phase 3 plans for abdakibart in HS
- Cross-filing actuarial verdict: inst-earnings + inst-offering context is an AMPLIFIER (PMI=6.20, q=0.000, n=548)
- No open-market insider buying corroborates the cluster (confluence score 23/100, divergent)
Financial Impact
11 institutions accumulated $180.7M in net new AVTX positions during Q2 2026, while 3 sellers reduced holdings by $4.1M, for a net institutional inflow of approximately $176.6M
Risk Factors
- 13F data is 45+ days stale; positions may have been unwound since quarter-end
- Cluster is dominated by mega-passive funds (State Street, Fidelity, BofA, Goldman Sachs) — signal may reflect index rebalancing rather than fundamental conviction
- No open-market insider buying to corroborate the institutional thesis
- Pre-revenue biotech with binary pipeline risk; Phase 3 for abdakibart not starting until H1 2027
- Historical calibration shows score-6 filings on AVTX have only 53% observed win rate at T+20
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-AVTX-2026-Q2 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $20.75 $16.69 | ▼ −19.57% | ▼ −17.61% | — |
Aug 17, 2026 6w ago | Institutional Cluster | $19.95 $16.07 | ▼ −19.45% | ▼ −17.47% | — |
Aug 6, 2026 8w ago | 8-K | $18.70 $19.00 | ▲ +1.60% | ▲ +1.00% | — |
Jun 16, 2026 15w ago | 8-K | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | — |
Jun 16, 2026 15w ago | Press Release | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | — |
Jun 8, 2026 16w ago | 8-K | $12.90 $19.25 | ▲ +49.22% | ▲ +47.78% | — |
May 13, 2026 20w ago | 8-K | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | — |
May 13, 2026 20w ago | Press Release | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | — |
May 6, 2026 21w ago | Press Release | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | — |
May 6, 2026 21w ago | Insider Cluster | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access